3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Drug Abuse -

Statin label to carry diabetes warning

Drug AbuseFeb 29, 12

All statin labels will now include a warning about a small increased risk for elevated blood glucose levels and possible problems with transient memory and cognition, the FDA announced today.

The agency will also remove existing recommendations to perform routine liver function tests on all patients taking the cholesterol-lowering medications, after concluding, “serious liver injury with statin use is rare and unpredicatable.”

“We want health care professionals and patients to have the most current information on the risks of statins, but also to assure them that these medications continue to provide an important health benefit of lowering cholesterol,” Mary Parks, MD, of the FDA’s Center for Drug Evaluation and Research, said in a press release.

Now clinicians need only perform liver enzyme tests before starting statin therapy and if a patient presents with symptoms of liver problems, including: unusual fatigue or weakness; loss of appetite; upper belly pain; dark-colored urine; yellowing of the skin or the whites of the eyes.

The labeling changes apply to atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), lovastatin extended-release (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor), and simvastatin (Zocor).

The new diabetes warning comes after hyperglycemia was observed in a substudy of the PROVE-IT TIMI 22 clinical trial in which researchers noted elevated blood glucose levels among patients treated with 40-mg atorvastatin. Additional data from a meta-analysis of 13 statin trials “reported that statin therapy was associated with a 9% increased risk for incident diabetes.”

Evidence to support the loss of memory and cognition with statins is less well defined and consists mostly of information from post-marketing adverse event reporting, according to the FDA. Most statin-associated memory impairment is reversible when the medication is discontinued.

In addition to these changes, the FDA has also modified labeling information for lovastatin (Mevacor), including a warning about the increased risk for myopathy and rhabdomylosis, and added a list of 10 contraindicated drugs or drug classes. These drugs include: itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir and nefazodone.


Nicole Blazek

Print Version
comments powered by Disqus

  FDA denies approval to wider use of J&J’s blood clot preventer
  FDA Warns of Potential Risk of Severe Liver Injury With Use of Dronedarone
  A mobile device for preventing and treating drug use
  White House announces plans to reduce prescription drug abuse
  Vioxx harmful even after patients stopped taking it
  Diabetes drugs warning: they cause heart problems
  FDA warns against fake online H1N1 remedy claims
  Row brews over ecstasy downgrade call
  FDA lacks access to food safety records: Congress
  Man says prescription drug caused gambling problem
  Rash most common side effect in Vectibix trials
  Man jailed for fake Viagra sales


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site